Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$75.95−2.25 (-2.88%)
Close on Nov 18, 2026Market cap $3.33BP/E –Yield 0.00%
Tarsus Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Tarsus Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $606.33M, up 105.2% year over year. For fiscal 2025 it was $451.36M, up 146.7% from the year before. The highest annual figure on record is $451.36M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.36M | +146.7% |
| FY2024 | Dec 31, 2024 | $182.95M | +948.6% |
| FY2023 | Dec 31, 2023 | $17.45M | -32.4% |
| FY2022 | Dec 31, 2022 | $25.82M | -54.7% |
| FY2021 | Dec 31, 2021 | $57.03M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $173.91M | +69.4% |
| Q1 FY2026 | Mar 31, 2026 | $162.05M | +106.9% |
| Q4 FY2025 | Dec 31, 2025 | $151.67M | +128.4% |
| Q3 FY2025 | Sep 30, 2025 | $118.70M | +146.7% |
| Q2 FY2025 | Jun 30, 2025 | $102.66M | +151.5% |
| Q1 FY2025 | Mar 31, 2025 | $78.34M | +183.7% |
| Q4 FY2024 | Dec 31, 2024 | $66.41M | +407.9% |
| Q3 FY2024 | Sep 30, 2024 | $48.12M | +2471.8% |
| Q2 FY2024 | Jun 30, 2024 | $40.81M | – |
| Q1 FY2024 | Mar 31, 2024 | $27.61M | +1004.6% |
| Q4 FY2023 | Dec 31, 2023 | $13.08M | +30.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.87M | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $2.50M | +363.8% |
| Q4 FY2022 | Dec 31, 2022 | $10.00M | +2858.6% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $15.28M | -30.6% |
| Q1 FY2022 | Mar 31, 2022 | $539.00K | -98.4% |
| Q4 FY2021 | Dec 31, 2021 | $338.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $1.24M | – |
| Q2 FY2021 | Jun 30, 2021 | $22.02M | – |
| Q1 FY2021 | Mar 31, 2021 | $33.43M | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
See a number that looks wrong?